- Home
- CCCC vs ZNTL Comparison
CCCC vs ZNTL Comparison
Compare CCCC & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- ZNTL
- Stock Information
- Founded
- CCCC 2015
- ZNTL 2014
- Country
- CCCC United States
- ZNTL United States
- Employees
- CCCC N/A
- ZNTL N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- CCCC Health Care
- ZNTL Health Care
- Exchange
- CCCC Nasdaq
- ZNTL Nasdaq
- Market Cap
- CCCC 405.6M
- ZNTL 238.2M
- IPO Year
- CCCC 2020
- ZNTL 2020
- Fundamental
- Price
- CCCC $6.25
- ZNTL $3.20
- Analyst Decision
- CCCC Buy
- ZNTL Buy
- Analyst Count
- CCCC 6
- ZNTL 7
- Target Price
- CCCC $10.50
- ZNTL $10.86
- AVG Volume (30 Days)
- CCCC 731.1K
- ZNTL 1.2M
- Earning Date
- CCCC 10-30-2024
- ZNTL 11-04-2024
- Dividend Yield
- CCCC N/A
- ZNTL N/A
- EPS Growth
- CCCC N/A
- ZNTL N/A
- EPS
- CCCC N/A
- ZNTL N/A
- Revenue
- CCCC $29,378,000.00
- ZNTL $40,560,000.00
- Revenue This Year
- CCCC $39.70
- ZNTL N/A
- Revenue Next Year
- CCCC N/A
- ZNTL N/A
- P/E Ratio
- CCCC N/A
- ZNTL N/A
- Revenue Growth
- CCCC 83.26
- ZNTL N/A
- 52 Week Low
- CCCC $1.06
- ZNTL $2.83
- 52 Week High
- CCCC $11.88
- ZNTL $18.24
- Technical
- Relative Strength Index (RSI)
- CCCC 54.57
- ZNTL 46.94
- Support Level
- CCCC $6.26
- ZNTL $2.92
- Resistance Level
- CCCC $7.14
- ZNTL $3.06
- Average True Range (ATR)
- CCCC 0.37
- ZNTL 0.17
- MACD
- CCCC 0.12
- ZNTL -0.00
- Stochastic Oscillator
- CCCC 58.99
- ZNTL 46.97
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.